Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and ...

Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.

12 13 Parkinsonism was further divided into three groups: PD (ie, idiopathic parkinsonism) was diagnosed, as in a previous study,9 based on the presence of two or more cardinal signs and after ...

The Parkinson’s disease patients were all current or past patients of the National Hospital for Neurology and Neurosurgery in London. They were recommended as probable cases of idiopathic Parkinson’s ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.

Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen dropped two antisense drugs in a pipeline cull and Voyager hit a setback for its ALS gene therapy.

Jan. 14, 2025 — There may be a link between hearing impairment and an increased risk of developing Parkinson's according to new research. This is one of the first studies to examine whether ...

Arvinas Inc. (ARVN) reported its earnings for the fourth quarter of 2024, revealing a smaller-than-expected loss per share ...

An experimental therapy for Parkinson's disease being developed by Roche and Prothena has missed the mark in a phase 2b trial, leaving them sifting through the data for signals of efficacy.

People with Parkinson's disease are more likely to develop certain types of dementia. Find out about the causes, symptoms and treatments. Parkinson’s disease is a brain disease that affects around 145 ...

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors ...